Synergy Pharmaceuticals, Inc. Financial Analysis ReviewSummarySynergy Pharmaceuticals, Inc. (Synergy) is a publicly traded development-stage biopharmaceutical company, engaged in developing drugs for the treatment of gastrointestinal (GI) conditions and diseases. The company's patented drug candidate, SP-304 is used to treat GI disorders, including Chronic Constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C). Currently, SP-304 is scheduled to enter a Phase 2a clinical trial in chronic constipation patients in the early 2010. In addition, the company is developing SP-333, a second generation GC-C receptor analog that targets GC-C receptors in the GI tract. Global Market Directs Financial Analysis Review is an essential source for data, analysis and insight into Synergy Pharmaceuticals, Inc. . It examines the companys business structure and operations, products and services. The report provides information regarding key data, details on key executives and the major locations and subsidiaries of the company. It also provides key financial ratios for the company.Scope The report includes key company information such as business description, products and services, and key suppliers and competitors. It provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters. Ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.Reasons to buy A quick one-stop-shop to understand the company. Get an in depth understanding of companys recent and historical financial performance. Get the latest metrics on companys performance. Support sales activities by understanding your customers businesses better Qualify prospective partners and suppliers. Understand and respond to your competitors business structure, strategy and prospects.
|
